Psilocybin mushrooms and public health in Brazil: a low-risk adverse event profile calls for evidence-based regulatory discussions - Nogueira, Marcel; García-Hernández, Solimary; Roberto, Gleicy Sotéro; Marques, Leonardo Zanella (medRxiv, 2024)
Background Current drug policy classifies psilocybin, a substance produced by psychoactive mushrooms, as having a high potential for abuse, neglecting its therapeutic properties. We aimed to investigate if psilocybin mushrooms pose a risk to Brazilian public health compared to other toxic agents and whether evidence-based regulatory discussions are needed.Methods A retrospective cross-sectional study was conducted following STROBE guidelines. Data were obtained from the Sistema de Agravos de Notificação (SINAN) on adverse events reported from 2007 to 2022. Participants were categorized into three groups: drug abuse, psilocybin mushrooms, and unknown mushrooms. Clinical outcomes assessed included non-hospitalization, hospitalization, and death. Associations between variables were analyzed using the Chi-square test.Results A total of 112,451 individuals sought medical attention for drug abuse-related adverse events. Among them, men constituted the majority (n = 79,514; 70.7%), followed by whites (n = 37,565; 33.4%) and those aged 26-35 (n = 29,163; 25.9%) (p < 0.001). Alcohol was the primary toxic agent (n = 71,824; 49.2%) (p < 0.001). The psilocybin mushroom group reported 13 adverse events, and the unknown mushroom group recorded 51 adverse events. Hospitalization rates were 19.5% (n = 21,923) for drug abuse, 46.2% (n = 6) for psilocybin mushrooms (0.02% of all hospitalizations) (99% CI: 10.6% - 81.6%), and 23.5% (n = 12) for unknown mushrooms (0.04% of hospitalizations) (99% CI: 8.3% - 38.7%). The mortality rate was 1.8% (n = 2035) for drug abuse, with no fatalities in the psilocybin or unknown mushroom groups. Most hospitalizations involved alcohol (45.0%), and deaths were mainly associated with cocaine (33.3%).Conclusion Our findings suggest that psilocybin mushrooms have a low-risk profile for adverse events, although underreporting may be a factor. This study highlights the need for evidence-based regulatory discussions to prevent arbitrary arrests and ensure safe access to psilocybin for clinical and ceremonial use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY anonymized and publicly available human data located at: https://datasus.saude.gov.br/transferencia-de-arquivos No additional ethical approvals were required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.https://datasus.saude.gov.br/transferencia-de-arquivos